ALBIS unveils next-gen healthcare materials at COMPAMED 2025
ALBIS will present a selection of advanced materials from its broad healthcare portfolio
ALBIS will present a selection of advanced materials from its broad healthcare portfolio
The new formulation features what Abbott calls a “triple care system,” anchored by a blend of nutrients aimed at supporting blood sugar control and metabolic health
Diversifying its portfolio to include late-phase antiviral agent
Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape
The trial will evaluate safety endpoints including dose-limiting toxicities and adverse events
False positive rates?ranged from 0% to 41%, meaning some labs incorrectly identified bacteria that weren’t present in the sample
Cardiovascular disease (CVD) is the leading cause of death in the US and worldwide with over 82 million Americans living with CVD
LANXESS will highlight its commitment to combatting antimicrobial resistance by presenting science-based disinfection solutions
Nearly 1 in 3 HbA1c test results fall within the diabetic range, while 1 in 4 individuals show signs of prediabetes
Subscribe To Our Newsletter & Stay Updated